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1420. Despite the astonishing advances that have been made in cardiacsurgery over the past 40 years, new-onset atrial fibrillation re-mains its most common complication. Long thought a nuisance, ithas now been clearly shown to increase length of stay, intensivecare unit utilization, morbidity, and even long-term mortality. Itoccurs in anywhere from 15% to 40% of patients and little
progress has been made in our understanding, prevention, or treatment of it.
Yagdi and colleagues1 have presented elsewhere in this issue of the Journal their
study on the use of amiodarone to prevent new-onset postoperative atrial fibrillation
(PAF) in patients undergoing coronary artery bypass grafting. They studied a group
of 157 subjects, randomly assigned to receive amiodarone after surgery or their
usual care without amiodarone. The drug was administered as an intravenous
infusion over 2 days, beginning immediately after surgery, followed by declining
oral dosing over a 30-day period. The investigators concluded that the postoperative
administration of amiodarone was effective at significantly reducing the incidence
of PAF by 14.6%, the average duration of PAF episodes by 21.9 hours, the average
ventricular response rate by 20 beats/min, and the average hospital length of stay by
1 day.
This excellent study provides additional substance to the growing body of
literature showing that amiodarone is an effective agent at reducing the incidence of
PAF,2-5 although not every study so far published agrees with this conclusion.6
What is not yet known, however, is whether amiodarone is a superior drug at
preventing PAF when compared with more standard lines of prophylaxis such as
-blockers.
To show that amiodarone should be the drug of choice against PAF, one must
address two issues: First, is amiodarone actually more potent than other drugs at
reducing the incidence of PAF, particularly in comparison with the inexpensive
-blockers? Second, is amiodarone cost-effective at reducing PAF, particularly
considering its expensive intravenous form?
There is actually very little information currently available addressing the po-
tency of amiodarone relative to other drugs, and what is available is fairly negative.
Wurdeman and colleagues7 recently performed a meta-analysis of the literature
concerning amiodarone versus sotalol and found that there was no difference in the
incidence of PAF or atrial flutter, length of hospital stay, or adverse drug reaction
between the drugs. Tokmakoglu and coworkers8 tested amiodarone against digoxin
and metoprolol in a randomized trial and found that both regimens proved effective
at reducing the incidence of PAF. Although PAF was less frequent in the amioda-
rone arm of this study (8% vs 16%), there was no statistical difference between these
two groups. In a study of amiodarone against propanolol, Solomon and colleagues9
were able to show that amiodarone was superior with regard to preventing PAF but
not with regard to length of stay. In the AMIBLOCK trial, the preliminary results
of which were recently presented in abstract form, amiodarone was shown to be less
effective and less safe than atenolol.10
The second question, cost-effectiveness, proves to be even more poorly answered
at this point. Referring to the Wurdeman study,7 a quick calculation reveals that
generic oral sotalol given at 120 mg daily for 7 days would cost about $25.
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Intravenous amiodarone costs $421 for a 150-mg ampule
and $1264 for a 450-mg infusion; patient charges would
typically be about 5 times higher. An intravenous 150-mg
loading dose of amiodarone followed by a 7-day oral course
of 1000 mg daily would cost approximately $475. Mahoney
and colleagues11 recently showed that amiodarone did not
prove cost-effective at reducing PAF except in older pa-
tients, particularly those with chronic lung disease (interest-
ingly, a group in which most practitioners would be reluc-
tant to prescribe amiodarone).
Therefore, although it is clear that amiodarone reduces
the incidence of PAF, it has not yet been determined
whether it is more potent or cost-effective than -blockers
or other class III antiarrhythmic drugs already in use. (In
fact, because amiodarone does possess some -blocking
effect, it is possible that this is the mechanism by which it
exerts its salutary actions.) As a measure of relief, one study
has shown that an inexpensive 7-day preoperative oral load-
ing regimen was effective at reducing PAF2; however, few
surgeons have the luxury of meeting their patients 7 days
before a cardiac operation!
Therefore, until more convincing evidence emerges, the
routine administration of -blockers remains standard pro-
phylaxis for PAF. Amiodarone should be reserved for those
patients in whom -blockade would be contraindicated or
who poorly tolerate the drug, such as those with poor
ventricular function, congestive heart failure, severe lung
disease, thyroid disease, or allergy.
References
1. Yagdi T, Nalbantgil S, Ayik F, et al. Amiodarone reduces the inci-
dence of atrial fibrillation after coronary artery bypass grafting. J Tho-
rac Cardiovasc Surg 203;125:1420-5.
2. Daoud EG, Strickberger SA, Man KC, et al. Preoperative amiodarone
as prophylaxis against atrial fibrillation after heart surgery. N Engl
J Med. 1997;337:1785-91.
3. Redle JD, Khurana S, Marzan R, et al. Prophylactic oral amiodarone
compared with placebo for prevention of atrial fibrillation after coro-
nary artery bypass surgery. Am Heart J. 1999;138:144-50.
4. Giri S, White CM, Dunn AB, et al. Oral amiodarone for prevention of
atrial fibrillation after open heart surgery, the atrial fibrillation sup-
pression trial (AFIST): a randomised placebo-controlled trial. Lancet.
2001;357:830-6.
5. Katariya K, DeMarchena E, Bolooki H. Oral amiodarone reduces
incidence of postoperative atrial fibrillation. Ann Thorac Surg. 1999;
68:1599-603.
6. Maras D, Boskovic SD, Popovic Z, et al. Single-day loading dose of
oral amiodarone for the prevention of new-onset atrial fibrillation after
coronary artery bypass surgery. Am Heart J. 2001;141:E8.
7. Wurdeman RL, Mooss AN, Mohiuddin SM, Lenz TL. Amiodarone vs
sotalol as prophylaxis against atrial fibrillation after heart surgery: a
meta-analysis. Chest. 2002;121:1203-10.
8. Tokmakoglu H, Kandemir O, Gunaydin S, Catav Z, Yorgancioglu C,
Zorlutuna Y. Amiodarone versus digoxin and metoprolol combination
for the prevention of postcoronary bypass atrial fibrillation. Eur J Car-
diothorac Surg. 2002;21:401-5.
9. Solomon AJ, Greenberg MD, Kilborn MJ, Katz NM. Amiodarone
versus a -blocker to prevent atrial fibrillation after cardiovascular
surgery. Am Heart J. 2001;142:811-5.
10. Zillo AC, de Zuloaga C, Guastavino D, et al. AMIBLOCK trial:
amiodarone vs. beta-blockers for prevention of post CABG atrial
tachyarrhythmias (abstract). Circulation. 2002;106(Suppl):II-605.
11. Mahoney EM, Thompson TD, Veledar E, Williams J, Weintraub WS.
Cost-effectiveness of targeting patients undergoing cardiac surgery for
therapy with intravenous amiodarone to prevent atrial fibrillation. J Am
Coll Cardiol. 2002;40:737-45.
Saltman Editorials
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 6 1203
ED
IT
O
RI
A
L
